U.S., Nov. 18 -- ClinicalTrials.gov registry received information related to the study (NCT07943741) titled 'Ketamine for Treatment of Alzheimers Disease Related Depression' on Oct. 30.

Brief Summary: Dementia is one of the major causes of disability and among older adults globally, with 6.7 million Americans living with Alzheimer's disease. Depression is common in people with cognitive and memory problems.

Depression in the elderly increases the risk of disability, medical comorbidity, cognitive impairment, and death. Patients with depression are at an increased risk of worsening cognition. Further, patients with depression are traditionally excluded from therapeutic trials in Alzheimer's Disease and other dementias. Current medications ...